진행성 두경부 상피세포암 환자에서 소분할 방사선조사 후의 치료반응 평가 = Evaluation of the Treatment Response after Hypofractionated Radiotherapy in Patients with Advanced Head and Neck Cancers

국문 초록 (Abstract)

목 적: 근치적 치료가 힘든 두경부 진행암 환자들을 대상으로 시행된 소분할 방사선조사의 치료반응 정도를 객관적
으로 평가해 보고, 이런 환자들에 대한 적절한 방사선치료 방법을 알아보고자 이 연구를 진행하였다. 대상 및 방법: 두경부에서 발생한 상피세포암종으로 진단되어 1998년부터 2008년까지 원발 병변 또는 림프절 병변에 대해 3 Gy 분할선량으로 고식적 소분할 방사선치료를 받았던 환자 31명을 대상으로 후향적 분석을 하였다. 대상 환자들의 방사선치료 전 컴퓨터단층촬영 영상자료를 통해 종양의 용적을 측정하였고, 이를 방사선치료 종료 후 2∼3개월째의 컴퓨터단층촬영 자료와 비교하여 치료반응을 평가하였다. 아울러 소분할 방사선치료로 인한 치료독성의 빈도와 정도를 확인하였고, 전체 생존율 및 무진행 생존율, 그리고 생존율이나 치료반응과 관련된 예후인자들 알아보고자 통계 분석 작업을 하였다. 결 과: 대상 환자들의 평균 연령은 70세였으며, 85%의 경우가 stage 4였다. 종양의 용적은 평균 128.4 cc였고, ECOG 활동점수 상 1점과 2점이 67.7%였다. 총방사선량은 24∼45 Gy (중간값 36 Gy)로 2명을 제외한 대부분의 환자가 30 Gy 이상 조사받았으며, 치료기간은 10∼25일이었다. 완전반응을 보인 경우가 4명(12.9%)이었고, 19명(61.3%)의 환자에서 부분반응을 보였다. 중간 생존기간은 8.9개월이었으며, 1년 무진행생존율은 12.9%였다. 치료반응 정도에 따른 생존율의 차이를 발견할 수 있었으며, 원발 부위, 병기, 종양의 용적, 방사선치료 범위, 총방사선량 등이 생존율이나 치료반응 정도와 유의한 관련이 있었다. 치료 기간 및 치료 종결 후 grade 4 이상의 치료독성은 없었다. 결 론: 소분할 방사선치료 결과 약 74%의 환자들에서 종양이 줄어드는 것을 객관적으로 확인할 수 있었다. 적절한 분할선량 및 추가 방사선치료가 필요한 환자들의 선별에 있어서는 추가적인 연구가 필요하겠다.

다국어 초록 (Multilingual Abstract)

Purpose: This study was performed to objectively evaluate the rate of tumor response to hypofractionated
radiotherapy for advanced squamous cell carcinomas of the head and neck. Materials and Methods: Thirty-one patients with advanced squamous cell carcinoma of the head and neck, who were treated by hypofractionated radiotherapy with 3 Gy per fraction for palliative purpose between 1998 and 2008, were reviewed retrospectively. Every tumor-volume was measured and evaluated from CT (computed tomography) images obtained before and 2∼3 months after radiotherapy. The radiation toxicity was assessed during and after radiotherapy. A statistical analysis was performed to investigate overall survival, progressionfree survival, and the prognostic factors for survival and response. Results: The median age of the study patients was 70 years. In addition, 85% of the patients were in stage 4 cancer and 66.7% had an ECOG performance status of 1∼2. The mean tumor-volume was 128.4 cc. Radiotherapy was administered with a total dose of 24∼45 Gy (median: 36 Gy) over 10∼25 days. Twenty-nine patients were treated with 30 Gy or more. The observed complete response rate was 12.9% and the partial response rate was 61.3%. Median survival time was 8.9 months and the 1-year progression-free survival rate was 12.9%. The treatment response rate was confirmed as a prognostic factor in the rate of survival. The primary site, stage, tumor-volume, radiotherapy field and overall radiation-dose showed a significant relationship with survival and treatment response. No grade 4 toxicity was observed during and after radiotherapy. Conclusion: There was an objective tumor-regression in about 74% of patients treated by hypofractionated radiotherapy. Further evaluation is needed to select the appropriate fraction-size and patient who may require the additional radiotherapy.

목차 (Table of Contents)

• 서 론
• 대상 및 방법
• 결 과
• 고안 및 결론

참고문헌 (Reference)

1 우홍균, "초기 성문암 환자에서의 소불할 조사법을 이용한 방사선치료:예비적 결과" 대한방사선종양학회 19 (19): 301-305, 2001

2 Corry J, "The ‘QUAD SHOT’- a phase II study of palliative radiotherapy for incurable head and neck cancer" 77 : 137-142, 2005

3 Hodson DI, "The role of palliative radiotherapy in advanced head and neck cancer" 6 (6): 54-60, 1996

4 Trotti A, "TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group" 8 : 613-624, 2007

5 Erkal HS, "Squamous cell carcinomas metastatic to cervical lymph nodes from an unknown head and neck mucosal site treated with radiation therapy with palliative intent" 59 : 319-321, 2001

6 Mohanti BK, "Short course palliative radiotherapy of 20 Gy in 5 fractions for advanced and incurable head and neck cancer: AIIMS study" 71 : 275-280, 2004

7 Weissberg JB, "Randomized trial of conventional versus high fractional dose radiation therapy in the treatment of advanced head and neck cancer" 8 : 179-185, 1982

8 Paris KJ, "Phase I-II study of multiple daily fractions for palliation of advanced head and neck malignancies" 25 : 657-660, 1993

9 Kowalski LP, "Natural history of untreated head and neck cancer" 36 : 1032-1037, 2000

10 Agarwal JP, "Hypofractionated, palliative radiotherapy for advanced head and neck cancer" 89 : 51-56, 2008

11 Porceddu SV, "Hypofractionated radiotherapy for the palliation of advanced head and neck cancer in patients unsuitable for curative treatment-“Hypo Trial”" 85 : 456-462, 2007

12 Weissberg JB, "High fractional dose irradiation of advanced head and neck cancer. Implications for combined radiotherapy and surgery" 109 : 98-102, 1983

13 Minatel E, "Combined radiotherapy and bleomycin in patients with inoperable head and neck cancer with unfavorable prognostic factors and severe symptoms" 34 : 119-122, 1998

14 Pignon JP, "Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer" 355 : 949-955, 2000

15 Carvalho AL, "A comparision of radiotherapy or radiochemotherapy with symptomatic treatment alone in patients with advanced head and neck carcinomas" 257 : 164-167, 2000